Overview

* CVRx ( CVRX ) Q2 revenue grows 15% yr/yr, beating analyst expectations, per LSEG data

* Net loss for Q2 was $14.7 mln, despite revenue growth

* CMS proposed favorable reimbursement changes for Barostim implant procedures

Outlook

* CVRx ( CVRX ) expects 2025 revenue between $13.7 mln and $14.7 mln for Q3

* CVRx ( CVRX ) narrows full-year 2025 revenue outlook between $55 mln and $57 mln

* Company expects 2025 gross margin of 83% to 84%

* CVRx ( CVRX ) anticipates 2025 operating expenses of $96 mln to $98 mln

Result Drivers

* US HF GROWTH - Revenue increase driven by expansion into new sales territories and accounts, and increased awareness of Barostim

* IMPLANTING CENTERS - Active implanting centers in the U.S. grew to 240, boosting revenue

* CMS PROPOSAL - Favorable reimbursement changes proposed by CMS for Barostim implant procedure

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $13.59 $13.20

Revenue mln mln (7

Analysts

)

Q2 EPS -$0.57

Q2 Net -$14.74

Income mln

Q2 Gross 84.0%

Margin

Q2 Basic -$0.57

EPS

Q2 Gross $11.45

Profit mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for CVRx Inc ( CVRX ) is $12.00, about 37% above its August 1 closing price of $7.56

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)